

**REMARKS*****III. Specification:***

The amendment to the specification is made merely to add a sequence identifier to the sequence described in Figure 2A, and does not add or constitute new matter. Moreover, the sequence described in Figure 2A (SEQ ID NO:1) is the same sequence described in Figure 1A (the GPRC5B-like gene described in the instant application and disclosed in SEQ ID NO:1). Support for the amendment can be found throughout the specification, claims and drawings as originally filed, and specifically can be found at page 7, lines 11-17, of the specification and in Figure 2A as originally filed.

***III. Drawings/Sequence Compliance:***

The Examiner has asserted that the instant application fails to comply with the requirements of 37 CFR 1.821 through 1.825, because the sequence disclosed in Figure 2A allegedly was not described in the sequence listing submitted with the application as filed. The Applicant contends that the sequence described in Figure 2A is identical to the sequence described as SEQ ID NO:1 in Figure 1A and in the original sequence listing, and thus submit that the sequence has been included in the sequence listing filed.

The Applicant has amended Figure 2A to include the inadvertently omitted sequence identifier. New Figure 2A with the amendment incorporated therein is attached herewith. The amendment to Figure 2A is merely the addition of the sequence identifier at the end of the sequence disclosed therein (SEQ ID NO:1). The amendment does not add or constitute new matter, and is completely supported by the application as originally filed. Specifically, support may be found at page 10, lines 5-9, of the specification, and in originally filed Figures 1A and 2A. As the sequence described in Figure 2A, to which the Examiner refers in the instant Office Action, is included in the sequence listing as previously filed (SEQ ID NO:1), and in light of the amendment to Figure 2A to more clearly identify the sequence as SEQ ID NO:1, the Applicant believes he is now in full compliance with the requirements of 37 CFR 1.821 through 1.825.

The Applicant contends that Sequence Listing submitted on December 12, 2001, in computer readable format (CRF) and paper, contains all sequences disclosed in the application. Therefore, Applicants believe that a substitute Sequence Listing in CRF is not required. Moreover, the content of the paper and computer readable copies of the Sequence Listing submitted on December 12, 2001 are identical. The sequence listing submitted in this application

merely presents nucleotide and/or amino acid sequences that appeared in the application as originally filed in accordance with 37 C.F.R. §1.821-1.825, thus no new matter has been introduced into the application.

**III. Requirement for Restriction:**

In response to the Examiner's requirement for restriction in the instant Office Action, the Applicant elects, without traverse, Group II (claims 3-9 and 14-18), drawn to a cell having a disruption in a GPRC5B-like gene, and transgenic animals having a disruption in a GPRC5B-like gene.

The Applicant respectfully requests entry and consideration of the foregoing amendments and remarks. Upon entry of the amendments, claims 3-9 and 14-18 are pending in the instant application.

Respectfully submitted,

Date: 8/4/03

Kelly J. Quast  
Kelly L. Quast, Reg. No. 52,141  
Deltagen, Inc.  
700 Bay Road  
Redwood City, CA 94063  
(650) 569-5100

Enclosures

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this correspondence and its listed enclosures is being deposited with the United States Postal Service as First Class Mail, postage paid, in an envelope addressed to: Commissioner for Patents, Alexandria, VA, Mail Stop Non- Fee Amendment/OIPE on August 4, 2003.

Name: Don Mixon

Signed: Don Mixon

Date: 8/4/03